Harrow, Inc. Current Assets
Harrow, Inc. (HROW) had Current Assets of $229.31 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-10
- 2026-06-30: Assets, Current $229.31M.
- 2026-03-31: Assets, Current $226.38M.
- 2025-12-31: Assets, Current $211.75M.
- 2025-09-30: Assets, Current $177.60M.
| Period end | Assets, Current | Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $229.31M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $226.38M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $211.75M 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $177.60M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $154.89M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $169.53M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $189.65M 10-K · filed 2026-03-02 | |
| 2024-09-30 | $147.06M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $139.39M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $125.46M 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $139.48M 10-K · filed 2025-03-27 | |
| 2023-09-30 | $110.28M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $60.30M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $51.69M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $118.26M 10-K · filed 2024-03-19 | |
| 2022-09-30 | $64.07M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $64.70M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $62.31M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $60.66M 10-K · filed 2023-03-23 | |
| 2021-09-30 | $91.13M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $93.47M 10-Q · filed 2021-08-10 | |
| 2021-03-31 | $40.64M 10-Q · filed 2021-05-11 | |
| 2020-12-31 | $40.98M 10-K · filed 2022-03-10 | $40.13M 10-K · filed 2021-03-08 |
| 2020-09-30 | $40.98M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $30.37M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $25.81M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $36.05M 10-K · filed 2021-03-08 | $36.77M 10-K · filed 2020-03-13 |
| 2019-09-30 | $32.37M 10-Q · filed 2019-11-13 | |
| 2019-06-30 | $38.12M 10-Q · filed 2019-08-14 | |
| 2019-03-31 | $38.51M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $32.84M 10-K · filed 2020-03-13 | |
| 2018-09-30 | $11.68M 10-Q · filed 2018-11-13 | |
| 2018-06-30 | $8.73M 10-Q · filed 2018-08-06 | |
| 2018-03-31 | $7.39M 10-Q · filed 2018-05-15 | |
| 2017-12-31 | $8.81M 10-K · filed 2019-03-12 | |
| 2017-09-30 | $10.10M 10-Q · filed 2017-11-14 | |
| 2017-06-30 | $10.36M 10-Q · filed 2017-08-10 | |
| 2017-03-31 | $13.60M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $14.75M 10-K · filed 2018-03-08 | |
| 2016-09-30 | $8.95M 10-Q · filed 2016-11-14 | |
| 2016-06-30 | $9.44M 10-Q · filed 2016-08-15 | |
| 2016-03-31 | $14.93M 10-Q · filed 2016-05-12 | |
| 2015-12-31 | $5.87M 10-K · filed 2017-03-21 | |
| 2015-09-30 | $9.37M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $12.01M 10-Q · filed 2015-08-12 | |
| 2015-03-31 | $4.61M 10-Q · filed 2015-05-13 | |
| 2014-12-31 | $9.06M 10-K · filed 2016-03-23 | $9.06M 10-K · filed 2015-03-12 |
| 2014-09-30 | $11.27M 10-Q · filed 2014-11-12 | |
| 2014-06-30 | $12.83M 10-Q · filed 2014-08-13 | |
| 2014-03-31 | $14.42M 10-Q · filed 2014-05-15 | |
| 2013-12-31 | $15.73M 10-K · filed 2015-03-12 | |
| 2013-09-30 | $17.38M 10-Q · filed 2013-11-06 | |
| 2013-06-30 | $18.36M 10-Q · filed 2013-08-14 | |
| 2013-03-31 | $19.23M 10-Q · filed 2013-05-08 | |
| 2012-12-31 | $10.69M 10-K · filed 2014-03-28 | |
| 2012-09-30 | $11.45M 10-Q · filed 2012-11-14 | |
| 2012-06-30 | $7.88M 10-Q · filed 2012-08-14 | |
| 2012-03-31 | $210.48K 10-Q · filed 2012-05-10 | |
| 2011-12-31 | $160.96K 10-K · filed 2013-03-18 | |
| 2011-09-30 | $76.52K 10-Q · filed 2012-02-23 | |
| 2011-06-30 | $76.33K 10-Q · filed 2012-02-23 | |
| 2010-12-31 | $351.95K 10-Q · filed 2012-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |